Deficiency of TLR9 does not affect autoantibody levels but shifts autoantibody specificity. Deficiency of TLR9 does not affect autoantibody levels but.

Slides:

Advertisements

Similar presentations

Subjects gain SLE classification through Systemic Lupus International Collaborating Clinics (SLICC) criteria of low complement, immunological manifestations.

Advertisements

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

The sting of WASP deficiency: autoimmunity exposed

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

MR1 inhibits anti-MTg autoantibody responses in CD28−/− NOD

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Fig. 5 A competent Fc is required for the antitumor immune response.

Stat3C/C mice are more prone to Th17 differentiation. A

Fig. 8 TLR8 exacerbates disease in the BLM-induced fibrosis model.

Volume 25, Issue 3, Pages (September 2006)

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Fig. 1. Thorase variants show defects in Thorase oligomer and GluA2-GRIP1 complex disassembly. Thorase variants show defects in Thorase oligomer and GluA2-GRIP1.

Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

TLR9 deficiency promotes aberrant T cell and myeloid dendritic cell (DC) phenotype in imiquimod-induced autoimmunity. TLR9 deficiency promotes aberrant.

Association of pretreatment interferon (IFN) signature metric (ISM) status with serum autoantibodies, BAFF levels and type I IFN bioactivity. Association.

Deficiency of TLR9 promotes more severe renal inflammation in imiquimod-induced autoimmunity. Deficiency of TLR9 promotes more severe renal inflammation.

Figure 3 Laquinimod (LAQ) reduces microglia infiltration and acute axonal damage after 6 weeks of cuprizone Laquinimod (LAQ) reduces microglia infiltration.

Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.

Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells. Neutrophil recruitment to the colonic lamina propria depends on CD4+ T cells.

Lymphadenopathy (at week 14) in the lpr-water, lpr-CU and lpr-TU groups of mice and ultrasoluble curcumin (UsC) uptake by Epstein–Barr virus (EBV) transformed.

Neutrophil depletion ameliorates colitis in Cx3cr1cre:Il10rafl/fl BM chimeras. Neutrophil depletion ameliorates colitis in Cx3cr1cre:Il10rafl/fl BM chimeras.

Mean (SD) AMG 557 serum concentration–time profiles following single-ascending dose (SAD) (A) and multiple-ascending dose (MAD) (B) administration AMG.

Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.

Longitudinal changes in serum G3BP concentrations and SLEDAI in 15 patients with SLE. Each plot represents one patient. Longitudinal changes in serum G3BP.

Positivity rate for antibodies to double-stranded DNA (anti-dsDNA), low complement, high complement C4 activation products (CBCAPS) and two-tiered methodology.

The earliest pathological changes of arthritis in gp130F759 develop at 5 months of age. The earliest pathological changes of arthritis in gp130F759 develop.

Anifrolumab does not elicit antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity. Anifrolumab does.

Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). Correlation.

Fig. 5 A competent Fc is required for the antitumor immune response.

Correlation between mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)

Anti-RNP/anti-Sm antibodies in sera (bleeds 1–5) and H&E stained sections of kidney/salivary gland of the MRL-lpr/lpr and MRL-MpJ mice provided with water,

Post-test probabilities of systemic lupus erythematosus (SLE) at different pretest probabilities for a positive and negative cell-bound complement activation.

Effect of dose level on the anti-keyhole limpet haemocyanin (KLH) IgG response in the multiple-ascending dose (MAD) study. Effect of dose level on the.

BAFF-deficient (BAFFnull) and anti-BAFF antibody (Ab)–treated obese mice exhibit superior glucose metabolic control compared with WT and Bnull mice. BAFF-deficient.

The effect of purified IgG from healthy controls or patients with lupus nephritis on tyrosine phosphorylation in podocytes at two different IgG concentrations.

Antinuclear antibody (ANA) patterns (using HEp-2 ANA assay kit) and anti-dsDNA (analysed by Crithidia luciliae assay) in sera of the lpr-water, lpr-CU.

Complement and antibody abnormalities at baseline and relation to disease activity clinical SELENA-SLEDAI (A) and PGA scores (B) in relation to the presence.

Change in urinary protein to creatinine ratio (uPCR) as a function of serum C4, C3, anti-C1q, EC4d, EC3d and ECR1. Change in urinary protein to creatinine.

The left side images are T2 fat-saturated axial images showing the relevant finding, and the right side images are coronal PD fat-saturated images with.

Distribution of the RAMRIS component scores sorted by pain score.

Association of MRI findings and serum autoantibodies in diffuse neuropsychiatric systemic lupus erythematosus. Association of MRI findings and serum autoantibodies.

Lack of Ctip2 is associated with impaired proliferation and delayed onset of differentiation during early stages of epidermal development. Lack of Ctip2.

SLE deconvolution patient clusters and representative immune cell types (A), and distribution of patients by SLE deconvolution cluster and treatment group—all.

Anti-DNA Abs were not affected by the deletion of GCs in pristane-induced lupus model. Anti-DNA Abs were not affected by the deletion of GCs in pristane-induced.

Increased autoantibodies in Bcl6FC mice.

Multivariate assay panel for systemic lupus erythematosus (SLE) diagnosis. Multivariate assay panel for systemic lupus erythematosus (SLE) diagnosis. Two-tier.

Least squares (LS) mean (SE) changes from baseline in (A) Cutaneous Lupus Erythematosus Disease Area and Severity Index activity scores and (B) Tender.

Antibody levels to Ro52, Ro60, p200 and La antigens in control and congenital heart block (CHB) cohort were measured as bound units (BU). Antibody levels.

Recruitment of epiplakin to keratin filaments and aggregates after application of various types of stress. Recruitment of epiplakin to keratin filaments.

Proportion of patients consulting their general practitioner for symptoms within each British Isles Lupus Activity Group (BILAG) domain in the 5 years.

Increased anti-DNA Abs in 2KO-Bcl6TC mice.

Increased autoantibodies in 2KO-Bcl6TC mice.

Serum anti-neuronal antibodies (anti-N) in patients with positive serum anti-GRP78. Serum anti-neuronal antibodies (anti-N) in patients with positive serum.

Number of microparticles (MPs) and distribution of MP surface markers in patients with SLE and HCs. Three aliquots of MPs were incubated with (1) anti-CD3,

Plots showing the difference in expression rate versus the difference in averaged transcript amount between patients with SLE with SLEDAI ≥10 and those.

Mean change from baseline over time in BILAG score,

mTORC1 is required for malignant transformation in the Eμ-Myc model.

Overall gene expression in monocyte subsets in patients and controls.

Anti-Flk-1 mAb treatment reduces vessel density in tumors.

(A) Mean urine protein/creatinine ratio (UPCR) and SEM in participants from the combined Lupus Nephritis Assessment of Rituximab (LUNAR) and A Study to.

p110δ activity is important for autoantibody responses.

Mean serum concentration time profiles of anifrolumab following subcutaneous and intravenous administration of anifrolumab.a aData below the limits of.

Serial determinations of both anti-chromatin and anti-dsDNA antibodies in a patient who developed lupus nephropathy during the study period, showing that.

Median percentage change in complement components 3 and 4 over time by SLE deconvolution cluster—all randomised and treated patients.* *Data from five.

TLR9 deficiency leads to more severe impairment of endothelium-dependent vasorelaxation and promotes aberrant B cell phenotype in imiquimod-induced autoimmunity.

Overall and recurrence-free survival.

Meningeal γδ T cell homeostasis is independent of inflammatory signals

In the absence of TLR5 and inflammasome recognition, FliC’s D2/D3 domains are essential for secondary IgG1 and IgG2c anti-flagellin responses. In the absence.

Fig. 1 Obesity-related adipocyte degeneration and cfDNA release.

Fig. 5 Effects of in vivo blockade of TLR9 on adipose tissue inflammation and insulin resistance in WT mice. Effects of in vivo blockade of TLR9 on adipose.

Presentation transcript:

Deficiency of TLR9 does not affect autoantibody levels but shifts autoantibody specificity. Deficiency of TLR9 does not affect autoantibody levels but shifts autoantibody specificity. WT and Tlr9-/- mice were treated with imiquimod for 3 weeks. Sera were collected and tested for (A) total IgG (WT-control n=5, Tlr9-/--control n=5, WT-imiquimod n=10, Tlr9-/--imiquimod n=10). (B) IgG anti-dsDNA autoantibodies (WT-control n=5, Tlr9-/--control n=4, WT-imiquimod n=10, Tlr9-/--imiquimod n=10). (C) IgG antihistone autoantibodies (WT-control n=5, Tlr9-/--control n=5, WT-imiquimod n=10, Tlr9-/--imiquimod n=10). (D) IgG anti-RNP/Sm autoantibodies (WT-control n=5, Tlr9-/--control n=4, WT-imiquimod n=10, Tlr9-/--imiquimod n=10). (E) Representative images of ANA. WT-control n=4, WT-imiquimod n=10, Tlr9-/--control n=4, Tlr9-/--imiquimod n=10. Bar, 75 µm. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. TLR, toll-like receptor; WT, wild type. Yudong Liu et al. Lupus Sci Med 2018;5:e000259 ©2018 by Lupus Foundation of America